I still have that distribution on my radar. I'll be working on it later this week. I'm sure we got dudded. So Q4 mmmmmmm - no further comment required
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling